Drugs / FE 999302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05571111 | Oct 2022 → Mar 2024 | infertility disorder | Ferring Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT03564509 | May 2018 → Oct 2019 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06511791 Comparator | Jul 2024 → Oct 2025 | infertility disorder | Ferring Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06466486 Comparator | Jun 2024 → Dec 2025 | infertility disorder | Ferring Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FE999302 | “This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle).” NCT06511791 ↗ |
| Known as | Choriogonadotropin beta | “This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle).” NCT06511791 ↗1“This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle).” NCT06466486 ↗ |
| Modality | Protein / enzyme biologic | “FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution” NCT03564509 ↗ |
| Route | Subcutaneous | “FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection” NCT03564509 ↗ |